申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:US05185333A1
公开(公告)日:1993-02-09
A benzazine compound, a geometrical isomer of said benzazine compound, an optical isomer of said benzazine compound, and a pharmaceutically acceptable salt of said benzazine compound, said benzazine compound being represented by formula (I): ##STR1## wherein each symbol is as defined in the specification. Said benzazine compounds exhibit 5-HT.sub.3 receptor antagonistic activity, and 5-HT.sub.1A receptor and/or 5-HT.sub.2 receptor and/or dopamine D.sub.2 receptor blocking activity so that they are useful as drugs for the prophylaxis or treatment of various digestive diseases vomiting and disturbances in central nervous systems and the like. The intermediates for said benzazine compounds are also disclosed.
一种苯嗪化合物,所述苯嗪化合物的几何异构体,所述苯嗪化合物的光学异构体,以及所述苯嗪化合物的药学可接受的盐,其中所述苯嗪化合物由式(I)表示:##STR1##其中每个符号如规范中定义。所述苯嗪化合物表现出5-HT.sub.3受体拮抗活性,以及5-HT.sub.1A受体和/或5-HT.sub.2受体和/或多巴胺D.sub.2受体阻断活性,因此它们可用作用于预防或治疗各种消化疾病、呕吐和中枢神经系统紊乱等药物。所述苯嗪化合物的中间体也被披露。